A detailed history of Vaughan & CO Securities, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Vaughan & CO Securities, Inc. holds 3,577 shares of ABBV stock, worth $601,114. This represents 0.42% of its overall portfolio holdings.

Number of Shares
3,577
Previous 3,967 9.83%
Holding current value
$601,114
Previous $614,000 6.03%
% of portfolio
0.42%
Previous 0.42%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

SELL
$159.82 - $182.1 $62,329 - $71,019
-390 Reduced 9.83%
3,577 $651,000
Q4 2023

Jan 26, 2024

SELL
$137.6 - $154.97 $11,971 - $13,482
-87 Reduced 2.15%
3,967 $614,000
Q3 2023

Oct 19, 2023

SELL
$133.59 - $154.65 $2,003 - $2,319
-15 Reduced 0.37%
4,054 $604,000
Q2 2023

Jul 20, 2023

SELL
$132.51 - $164.9 $2,650 - $3,298
-20 Reduced 0.49%
4,069 $548,000
Q1 2023

Apr 18, 2023

SELL
$144.61 - $166.54 $145,766 - $167,872
-1,008 Reduced 19.78%
4,089 $651,000
Q4 2022

Feb 02, 2023

SELL
$138.31 - $165.87 $27,247 - $32,676
-197 Reduced 3.72%
5,097 $824,000
Q3 2022

Oct 21, 2022

SELL
$134.21 - $153.93 $9,931 - $11,390
-74 Reduced 1.38%
5,294 $711,000
Q1 2022

Apr 21, 2022

SELL
$131.98 - $163.75 $7,786 - $9,661
-59 Reduced 1.09%
5,368 $870,000
Q1 2021

May 14, 2021

SELL
$102.3 - $112.62 $176,672 - $194,494
-1,727 Reduced 24.14%
5,427 $587,000
Q4 2020

May 11, 2021

SELL
$80.49 - $108.67 $28,815 - $38,903
-358 Reduced 4.77%
7,154 $767,000
Q3 2020

May 10, 2021

SELL
$85.91 - $100.83 $15,893 - $18,653
-185 Reduced 2.4%
7,512 $658,000
Q2 2020

May 10, 2021

SELL
$73.37 - $98.18 $10,491 - $14,039
-143 Reduced 1.82%
7,697 $756,000
Q1 2020

May 28, 2020

SELL
$64.5 - $97.79 $4,386 - $6,649
-68 Reduced 0.86%
7,840 $597,000
Q4 2019

Feb 04, 2020

BUY
$72.13 - $90.25 $570,404 - $713,697
7,908 New
7,908 $700,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Vaughan & CO Securities, Inc. Portfolio

Follow Vaughan & CO Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vaughan & CO Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vaughan & CO Securities, Inc. with notifications on news.